PT3336097T - Preparação da forma não cristalina de ácido obeticólico - Google Patents

Preparação da forma não cristalina de ácido obeticólico

Info

Publication number: PT3336097T
Authority: PT; Portugal
Prior art keywords: preparation; crystalline form; obeticholic acid; obeticholic; acid
Prior art date: 2012-06-19

Application number

PT172029167T

Other languages

English (en)

Original Assignee

Intercept Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-06-19

Filing date

2013-06-17

Publication date

2020-10-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48741553&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3336097(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-06-17 Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc

2020-10-29 Publication of PT3336097T publication Critical patent/PT3336097T/pt

Links

ZXERDUOLZKYMJM-ZWECCWDJSA-N obeticholic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)CCC(O)=O)CC[C@H]21 ZXERDUOLZKYMJM-ZWECCWDJSA-N 0.000 title 1
229960001601 obeticholic acid Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Gastroenterology & Hepatology (AREA)
Virology (AREA)
Diabetes (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Obesity (AREA)
Molecular Biology (AREA)
Vascular Medicine (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

PT172029167T 2012-06-19 2013-06-17 Preparação da forma não cristalina de ácido obeticólico PT3336097T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201261661531P	2012-06-19	2012-06-19

Publications (1)

Publication Number	Publication Date
PT3336097T true PT3336097T (pt)	2020-10-29

Family

ID=48741553

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT172029167T PT3336097T (pt)	2012-06-19	2013-06-17	Preparação da forma não cristalina de ácido obeticólico

Country Status (25)

Country	Link
US (9)	US9238673B2 (pt)
EP (4)	EP3789394A1 (pt)
JP (6)	JP2015521621A (pt)
KR (4)	KR20150022974A (pt)
CN (2)	CN111228278A (pt)
AU (5)	AU2013277429B2 (pt)
BR (2)	BR122016011808B1 (pt)
CA (3)	CA3028207A1 (pt)
CL (2)	CL2014003475A1 (pt)
CO (1)	CO7240414A2 (pt)
DK (1)	DK3336097T3 (pt)
EA (2)	EA201990211A1 (pt)
ES (1)	ES2822375T3 (pt)
HK (1)	HK1211296A1 (pt)
IL (3)	IL236231A0 (pt)
IN (1)	IN2014MN02561A (pt)
MX (2)	MX365059B (pt)
NZ (3)	NZ703072A (pt)
PH (1)	PH12014502835A1 (pt)
PL (1)	PL3336097T3 (pt)
PT (1)	PT3336097T (pt)
SG (3)	SG10201607230SA (pt)
SI (1)	SI3336097T1 (pt)
TW (1)	TWI673284B (pt)
WO (1)	WO2013192097A1 (pt)

Families Citing this family (175)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2248581T3 (es)	2001-03-12	2006-03-16	Intercept Pharmaceuticals, Inc.	Esteroides como agonistas de fxr.
US9719068B2 (en)	2010-05-06	2017-08-01	Children's Hospital Medical Center	Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
EP2545964A1 (en)	2011-07-13	2013-01-16	Phenex Pharmaceuticals AG	Novel FXR (NR1H4) binding and activity modulating compounds
SI3336097T1 (sl)	2012-06-19	2021-07-30	Intercept Pharmaceuticals, Inc.	Priprava nekristalinične oblike obetiholne kisline
US9982008B2 (en)	2012-06-19	2018-05-29	Intercept Pharmaceuticals, Inc.	Preparation and uses of obeticholic acid
AU2013352288B2 (en) *	2012-11-28	2017-11-23	Intercept Pharmaceuticals, Inc.	Treatment of pulmonary disease
US9814733B2 (en) *	2012-12-31	2017-11-14	A,arin Pharmaceuticals Ireland Limited	Compositions comprising EPA and obeticholic acid and methods of use thereof
WO2014169836A1 (en)	2013-04-17	2014-10-23	Sage Therapeutics, Inc.	19-nor neuroactive steroids and methods of use thereof
WO2014169831A1 (en)	2013-04-17	2014-10-23	Sage Therapeutics, Inc.	19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
JP6470258B2 (ja)	2013-04-17	2019-02-13	セージセラピューティクス，インコーポレイテッド	１９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法
ES2807264T3 (es)	2013-04-17	2021-02-22	Sage Therapeutics Inc	Esteroides neuroactivos 19-nor para métodos de tratamiento
WO2015010054A2 (en)	2013-07-19	2015-01-22	Sage Therapeutics, Inc.	Neuroactive steroids, compositions, and uses thereof
ES2848823T3 (es)	2013-08-23	2021-08-12	Sage Therapeutics Inc	Esteroides neuroactivos, composiciones y usos de los mismos
CN106661548B (zh)	2014-05-28	2020-12-11	儿童医院医疗中心	用于经由定向分化将前体细胞转化为胃组织的方法和系统
SMT202000070T1 (it) *	2014-05-29	2020-03-13	Bar Pharmaceuticals S R L	Derivati del colano per l'uso del trattamento e/o la prevenzione di malattie mediate da fxr e tgr5/gpbar1
WO2015195962A1 (en)	2014-06-18	2015-12-23	Sage Therapeutics, Inc.	Neuroactive steroids, compositions, and uses thereof
CN106459136B (zh) *	2014-09-28	2018-06-26	江苏盛迪医药有限公司	一种奥贝胆酸的制备方法
US10577390B2 (en)	2014-10-16	2020-03-03	Sage Therapeutics, Inc.	Compositions and methods for treating CNS disorders
ME03809B (me)	2014-10-16	2021-04-20	Sage Therapeutics Inc	KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a
JP6804438B2 (ja)	2014-10-17	2020-12-23	チルドレンズホスピタルメディカルセンター	多能性幹細胞を使用するヒト小腸のｉｎｖｉｖｏモデル、並びにそれを作製、及び使用する方法
SG11201703717SA (en)	2014-11-06	2017-06-29	Enanta Pharm Inc	Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
KR102546748B1 (ko)	2014-11-19	2023-06-22	엔제트피 유케이 리미티드	스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-3,7-다이온 스테로이드
EA033445B1 (ru)	2014-11-19	2019-10-31	Nzp Uk Ltd	5-бета-6-алкил-7-гидрокси-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
KR102527821B1 (ko)	2014-11-19	2023-05-02	엔제트피 유케이 리미티드	스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-6,7-다이온 스테로이드
CN107207559B (zh)	2014-11-19	2019-10-25	Nzp英国有限公司	作为制备类固醇fxr调节剂的中间体的6-烷基-7-羟基-4-烯-3-酮类固醇
US10208081B2 (en)	2014-11-26	2019-02-19	Enanta Pharmaceuticals, Inc.	Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
EP3223823A4 (en)	2014-11-26	2018-10-17	Enanta Pharmaceuticals, Inc.	Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
US11578097B2 (en)	2014-11-26	2023-02-14	Enanta Pharmaceuticals, Inc.	Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
WO2016082789A1 (en)	2014-11-27	2016-06-02	Sage Therapeutics, Inc.	Compositions and methods for treating cns disorders
CN105777835B (zh) *	2014-12-25	2020-02-14	重庆药友制药有限责任公司	一种制备鹅去氧胆酸类似物的方法
CN105801653B (zh) *	2014-12-30	2018-04-17	苏州晶云药物科技有限公司	奥贝胆酸的晶型a及其制备方法
CN105859814A (zh) *	2015-01-23	2016-08-17	江苏奥赛康药业股份有限公司	一种奥贝胆酸化合物及其药物组合物
WO2016123056A1 (en)	2015-01-26	2016-08-04	Sage Therapeutics, Inc.	Compositions and methods for treating cns disorders
TW201628625A (zh)	2015-02-06	2016-08-16	英特賽普醫藥品公司	組合療法醫藥組成物
EP3256134A4 (en)	2015-02-11	2018-10-03	Enanta Pharmaceuticals, Inc.	Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
CN105985395A (zh) *	2015-02-13	2016-10-05	江苏奥赛康药业股份有限公司	一种奥贝胆酸化合物及含有该化合物的药物组合物
CN105985396A (zh) *	2015-02-16	2016-10-05	苏州泽璟生物制药有限公司	氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物
EP4155314A1 (en)	2015-02-20	2023-03-29	Sage Therapeutics, Inc.	Neuroactive steroids, compositions, and uses thereof
CN107530361A (zh) *	2015-03-09	2018-01-02	英特塞普特医药品公司	用于调节骨密度的方法
WO2016161003A1 (en)	2015-03-31	2016-10-06	Enanta Phamraceuticals, Inc.	Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
US10894054B2 (en)	2015-04-07	2021-01-19	Intercept Pharmaceuticals, Inc.	FXR agonist compositions for combination therapy
CN105777836A (zh) *	2015-04-09	2016-07-20	厦门蔚扬药业有限公司	奥贝胆酸的多晶型物及其制备方法
WO2016168553A1 (en) *	2015-04-17	2016-10-20	Concert Pharmaceuticals, Inc.	Deuterated obeticholic acid
PE20180690A1 (es)	2015-04-27	2018-04-23	Intercept Pharmaceuticals Inc	Composiciones de acido obeticolico y metodos de uso
CN106290594B (zh) *	2015-05-27	2020-07-17	中美华世通生物医药科技（武汉）有限公司	测定奥贝胆酸片溶出含量的方法
CN105294801A (zh) *	2015-07-02	2016-02-03	扬子江药业集团南京海陵药业有限公司	6-乙基鹅去氧胆酸异构体的合成及其分离测定方法
CZ2015504A3 (cs)	2015-07-16	2017-01-25	Zentiva, K.S.	Krystalické formy obeticholové kyseliny
EP3124080A1 (en) *	2015-07-28	2017-02-01	Merz Pharma GmbH & Co. KGaA	Semisynthetic bile acids for injection lipolysis
CN105085597B (zh) *	2015-08-28	2017-03-29	成都百裕制药股份有限公司	一种无定型奥贝胆酸的制备方法
CN106478756A (zh) *	2015-09-02	2017-03-08	中美华世通生物医药科技（武汉）有限公司	Oca-e单晶及其制备方法和用途
CA2998876A1 (en) *	2015-09-21	2017-03-30	Intercept Pharmaceuticals, Inc.	Methods of promoting hepatic regeneration
AU2016325619A1 (en)	2015-09-24	2018-04-12	Intercept Pharmaceuticals, Inc.	Methods and intermediates for the preparation bile acid derivatives
MA42339A1 (fr)	2015-10-07	2019-01-31	Intercept Pharmaceuticals Inc	Modulateurs du récepteur farnésoïde x
CN106589039B (zh) *	2015-10-15	2019-12-17	苏州朗科生物技术股份有限公司	一种奥贝胆酸的制备方法及相关化合物
CN106589038A (zh) *	2015-10-15	2017-04-26	重庆医药工业研究院有限责任公司	一种制备3α,7α-二羟基-6α-乙基-5β-胆烷酸的方法
CN106632564B (zh) *	2015-10-30	2021-04-13	苏州泽璟生物制药股份有限公司	奥贝胆酸盐及其无定形物和药物组合物
CN106668027A (zh) *	2015-11-05	2017-05-17	中美华世通生物医药科技（武汉）有限公司	奥贝胆酸药物组合物及其制备方法
AU2016350690C1 (en) *	2015-11-06	2020-04-23	Intercept Pharmaceuticals, Inc.	Methods for the preparation of obeticholic acid and derivatives thereof
CN106749466B (zh) *	2015-11-23	2019-05-21	南京济群医药科技股份有限公司	一种高纯度奥贝胆酸的制备方法
CN105315320B (zh) *	2015-11-30	2017-03-08	山东省药学科学院	一种制备奥贝胆酸的方法
CN106810587A (zh) *	2015-12-01	2017-06-09	中美华世通生物医药科技（武汉）有限公司	制备无定型奥贝胆酸的方法
CN106810586A (zh) *	2015-12-01	2017-06-09	中美华世通生物医药科技（武汉）有限公司	奥贝胆酸晶型ⅱ及其制备方法和用途
CN106822005A (zh) *	2015-12-03	2017-06-13	江苏先声药业有限公司	奥贝胆酸组合物及其制备方法
CN106854229A (zh) *	2015-12-08	2017-06-16	陈剑	一类脂肪酸盐,其制备及其在医药上的应用
CN105481925B (zh) *	2015-12-17	2018-06-22	南京济群医药科技股份有限公司	一种奥贝胆酸及其中间体的制备方法
JP2018538331A (ja) *	2015-12-22	2018-12-27	インターセプトファーマシューティカルズ，インコーポレイテッド	オベチコール酸の多型結晶形態
CN105399793A (zh) *	2015-12-24	2016-03-16	北京康立生医药技术开发有限公司	一种胆烷酸的制备方法
CN106916195A (zh) *	2015-12-25	2017-07-04	中美华世通生物医药科技（武汉）有限公司	奥贝胆酸中间体的纯化方法
WO2017115324A1 (en) *	2016-01-01	2017-07-06	Lupin Limited	Solid forms of obeticholic acid and processes thereof
CN105566429B (zh) *	2016-01-22	2020-12-01	南京长澳医药科技有限公司	一种奥贝胆酸1型的制备方法
CN105646633B (zh) *	2016-01-22	2020-05-26	南京长澳医药科技有限公司	一种制备奥贝胆酸1型的方法
CN105646634A (zh) *	2016-01-29	2016-06-08	中国药科大学	奥贝胆酸杂质的制备方法
JP6842474B2 (ja)	2016-02-02	2021-03-17	深▲セン▼市塔吉瑞生物医▲薬▼有限公司ＳｈｅｎｚｈｅｎＴａｒｇｅｔＲｘ，Ｉｎｃ．	ステロイド系化合物、当該化合物を含む組成物及びその使用
US11364226B2 (en)	2017-06-30	2022-06-21	Cinrx Pharma, Llc	Deuterated domperidone compositions, methods, and preparation
WO2017136617A1 (en) *	2016-02-04	2017-08-10	Cinrx Pharma, Llc	Deuterated domperidone compositions and methods for therapy of disorders
ES2909907T3 (es) *	2016-02-10	2022-05-10	Dr Reddys Laboratories Ltd	Proceso de purificación que implica la sal de amina del ácido obeticólico
WO2017147174A1 (en)	2016-02-23	2017-08-31	Enanta Pharmaceuticals, Inc.	Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
WO2017147159A1 (en)	2016-02-23	2017-08-31	Enanta Pharmaceuticals, Inc.	Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
US10323060B2 (en)	2016-02-23	2019-06-18	Enanta Pharmaceuticals, Inc.	Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
CN107126419B (zh) *	2016-02-26	2020-06-19	石药集团中诺药业（石家庄）有限公司	一种奥贝胆酸片剂及其制备方法
CN106008639B (zh) *	2016-03-11	2019-01-08	深圳市塔吉瑞生物医药有限公司	用于预防或治疗fxr-介导疾病的胆烷酸化合物
CN105541953B (zh) *	2016-03-15	2017-11-21	成都市新功生物科技有限公司	一种高纯度奥贝胆酸的重结晶纯化方法
CN107188917A (zh) *	2016-03-15	2017-09-22	正大天晴药业集团股份有限公司	奥贝胆酸盐及其药物组合物
JPWO2017170434A1 (ja) *	2016-03-28	2019-01-31	インターセプトファーマシューティカルズ，インコーポレイテッド	Ｆｘｒアゴニストとａｒｂの組み合わせ医薬
WO2017167233A1 (zh) *	2016-03-31	2017-10-05	江苏恒瑞医药股份有限公司	一种奥贝胆酸的新结晶形式及其制备方法
WO2017170858A1 (ja)	2016-03-31	2017-10-05	大日本住友製薬株式会社	溶出性に優れた経口製剤
ES2901598T3 (es)	2016-03-31	2022-03-23	Intercept Pharmaceuticals Inc	Comprimido recubierto con película que tiene una alta estabilidad química del ingrediente activo
EP3228306A1 (en)	2016-04-04	2017-10-11	ratiopharm GmbH	Complex compound comprising obeticholic acid and cyclodextrin and pharmaceutical formulation comprising the complex compound
WO2017174515A1 (en)	2016-04-04	2017-10-12	Dipharma Francis S.R.L.	Method for preparing a farnesoid x receptor agonist
TW201738254A (zh) *	2016-04-19	2017-11-01	英特賽普醫藥品公司	奧貝膽酸及其衍生物之製備方法
ES2929758T3 (es)	2016-05-05	2022-12-01	Childrens Hospital Med Ct	Métodos para la fabricación in vitro de tejido del fondo gástrico y composiciones relacionadas con el mismo
CN105859817A (zh) *	2016-05-09	2016-08-17	成都宇西医药技术有限公司	一种制备3α-羟基-6-乙烯基-7-酮基-5β-胆烷酸的方法
GB201608777D0 (en)	2016-05-18	2016-06-29	Dextra Lab Ltd	Compounds
CN107400154A (zh) *	2016-05-18	2017-11-28	北京凯因科技股份有限公司	一种制备3α,7α-二-羟基-6α-乙基-5β-胆烷酸的方法
GB201608776D0 (en)	2016-05-18	2016-06-29	Dextra Lab Ltd	Methods and compounds
CN106046094A (zh) *	2016-05-30	2016-10-26	福建广生堂药业股份有限公司	一种奥贝胆酸二聚体杂质及其制备方法
CN105859818A (zh) *	2016-05-31	2016-08-17	四川瑞希康生物医药有限公司	一种奥贝胆酸α晶型及其制备方法、药物组合物和用途
EP3464316A4 (en)	2016-06-01	2020-02-19	Dr. Reddy's Laboratories Ltd.	PROCESS FOR THE PREPARATION OF OBETICHOLIC ACID
CN105997909A (zh) *	2016-06-02	2016-10-12	中国药科大学	一种奥贝胆酸口崩片及其制备方法
MX385718B (es)	2016-06-13	2025-03-18	Gilead Sciences Inc	Compuestos moduladores de fxr (nr1h4).
CA3252823A1 (en)	2016-06-13	2025-02-25	Gilead Sciences, Inc.	Substituted tert-butyl-3-(2-chloro-phenyl)-3-hydroxyazetidine-1-carboxylate compounds
CN106083971B (zh) *	2016-06-17	2017-11-14	苏州敬业医药化工有限公司	一种(E)‑3α‑羟基‑6‑亚乙基‑7‑酮‑5β‑胆烷‑24‑酸的制备方法
CZ2016385A3 (cs)	2016-06-28	2018-01-10	Zentiva, K.S.	Způsoby přípravy intermediátů pro syntézu Obeticholové kyseliny
CN107540720B (zh) *	2016-06-29	2021-03-02	常州市第四制药厂有限公司	3α,7α-二羟基-6α-乙基-5β-胆烷酸晶型H及其制备方法和应用
MA45599A (fr)	2016-07-11	2019-05-15	Sage Therapeutics Inc	Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation
US20190233465A1 (en)	2016-07-11	2019-08-01	Sage Therapeutics, Inc.	C7, c12, and c16 substituted neuroactive steroids and their methods of use
CN107648190B (zh) *	2016-07-26	2021-04-27	海南先声药业有限公司	奥贝胆酸组合物及其制备方法
CN106279331B (zh) *	2016-07-27	2019-06-14	宋火良	胆酸类肝病治疗药物
CN107674106B (zh) *	2016-08-01	2021-06-22	华北制药集团新药研究开发有限责任公司	一种奥贝胆酸二聚体的制备方法
CN106279335A (zh) *	2016-08-12	2017-01-04	齐鲁制药有限公司	一种制备奥贝胆酸及其中间体的方法
EP3287467A1 (en)	2016-08-22	2018-02-28	ratiopharm GmbH	Preparation of obeticholic acid comprising continuous flow process steps
CN115490744A (zh) *	2016-08-29	2022-12-20	山东新时代药业有限公司	一种3α-羟基-6α-乙基-7-酮-5β-胆-24-酸的制备方法
CN107778339A (zh) *	2016-08-29	2018-03-09	鲁南制药集团股份有限公司	一种无定型奥贝胆酸的制备方法
EP3293196A1 (en)	2016-09-09	2018-03-14	Hexal AG	Process for purifying obeticholic acid
CN106478757B (zh) *	2016-09-27	2019-01-18	华南理工大学	一种3α,7α-二羟基-6α-乙基胆烷酸的制备方法
KR20190057108A (ko) *	2016-09-30	2019-05-27	인터셉트 파마슈티컬즈, 인크.	담즙산 유도체의 결정형
CN107976506B (zh) *	2016-10-25	2020-05-12	成都弘达药业有限公司	一种奥贝胆酸有关物质的检测方法
KR102729404B1 (ko)	2016-11-04	2024-11-14	칠드런즈 호스피탈 메디칼 센터	간 유사 장기 조성물 및 이를 제조 및 사용하는 방법
CN110121347A (zh) *	2016-11-29	2019-08-13	英安塔制药有限公司	制备磺酰脲胆汁酸衍生物的方法
JP7068305B2 (ja)	2016-12-05	2022-05-16	チルドレンズホスピタルメディカルセンター	結腸オルガノイドならびにその作製方法および使用方法
BR112019011740A2 (pt) *	2016-12-09	2019-10-29	Cadila Healthcare Limited	composição farmacêutica e método para o tratamento de colangite biliar primária
CN108614038B (zh) *	2016-12-13	2022-05-17	亚宝药业集团股份有限公司	一种测定奥贝胆酸原料药有关物质的方法
CN106749472B (zh) *	2016-12-30	2019-02-22	江苏开元医药化工有限公司	一种3α-羟基-6α-乙基-7-酮-5β-胆烷-24-酸的制备方法
CN106645497A (zh) *	2017-01-03	2017-05-10	山东省药学科学院	一种奥贝胆酸及其制剂中有关物质的检测方法
MX2019008510A (es)	2017-01-18	2019-11-11	Tremco Inc	Compuesto de union estructural.
US10472386B2 (en)	2017-02-14	2019-11-12	Enanta Pharmaceuticals, Inc.	Bile acid derivatives as FXR agonists and methods of use thereof
CN106892954B (zh) *	2017-02-23	2019-04-30	广州隽沐生物科技有限公司	奥贝胆酸的制备工艺
CN110831602A (zh) *	2017-03-08	2020-02-21	英特塞普特医药品公司	奥贝胆酸的结晶形式
PT3600309T (pt)	2017-03-28	2022-10-03	Gilead Sciences Inc	Combinações terapêuticas para o tratamento de doenças hepáticas
CN108659086A (zh) *	2017-03-29	2018-10-16	杭州源昶医药科技有限公司	一种奥贝胆酸的合成方法
BR112019020780A2 (pt)	2017-04-07	2020-04-28	Enanta Pharm Inc	processo para preparação de derivados de ácido biliar de carbamato de sulfonila
US12281334B2 (en)	2017-04-14	2025-04-22	Children's Hospital Medical Center	Multi donor stem cell compositions and methods of making same
CN106986910A (zh) *	2017-04-19	2017-07-28	成都百特万合医药科技有限公司	奥贝胆酸中间体的制备方法
CN110799519B (zh) *	2017-04-20	2023-02-28	大雄Bio株式会社	利用连续流动反应的胆汁酸衍生物的制备方法
WO2018211413A1 (en) *	2017-05-15	2018-11-22	Dr. Reddy’S Laboratories Limited	Solid forms of obeticholic acid and process for preparation
CZ2017298A3 (cs)	2017-05-26	2018-12-05	Zentiva, K.S.	Amorfní formy obeticholové kyseliny
CN107286160A (zh) *	2017-06-05	2017-10-24	毛佳婧	一种抗肝炎药物的哌啶并吡啶并吡唑‑锌配合物的制备方法
BR112019027458A2 (pt) *	2017-06-23	2020-07-07	Intercept Pharmaceuticals, Inc.	métodos e intermediários para a preparação de derivados de ácidos biliares
US12478612B2 (en)	2017-06-30	2025-11-25	Cindome Pharma, Inc.	Deuterated domperidone compositions, methods, and preparation
CN109280071A (zh) *	2017-07-19	2019-01-29	东莞东阳光药物研发有限公司	奥贝胆酸的晶型及其制备方法
CA3070837A1 (en)	2017-07-24	2019-01-31	Intercept Pharmaceuticals, Inc.	Isotopically labeled bile acid derivatives
KR102388809B1 (ko)	2017-08-03	2022-04-21	(주)메디톡스	담즙산류를 제조하기 위한 방법
CN107383139A (zh) *	2017-08-09	2017-11-24	杭州和泽医药科技有限公司	一种3α‑羟基‑7‑氧代‑5β‑胆烷酸新衍生物制备奥贝胆酸的方法
CN109485687A (zh) *	2017-09-12	2019-03-19	成都弘达药业有限公司	奥贝胆酸的晶型j及其制备方法
EP3694603B1 (en)	2017-10-10	2026-04-08	Children's Hospital Medical Center	Esophageal tissue and/or organoid compositions and methods of making same
US10611793B1 (en)	2017-11-27	2020-04-07	Teva Czech Industries S.R.O.	Solid state forms of obeticholic acid salts
WO2019106043A1 (en)	2017-11-29	2019-06-06	Hexal Ag	Pharmaceutical composition comprising obeticholic acid
EP3720867A1 (en)	2017-12-08	2020-10-14	Sage Therapeutics, Inc.	Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders
US12379372B2 (en)	2017-12-21	2025-08-05	Children's Hospital Medical Center	Digitalized human organoids and methods of using same
WO2019145977A1 (en) *	2018-01-25	2019-08-01	Msn Laboratories Private Limited, R&D Center	PROCESS FOR THE PREPARATION OF 3α,7α-DIHYDROXY6α-ETHYL-5β-CHOLAN-24-OIC ACID
CN108440629A (zh) *	2018-03-16	2018-08-24	丽珠集团新北江制药股份有限公司	一种制备奥贝胆酸中间体及奥贝胆酸的方法
WO2019197962A1 (en) *	2018-04-09	2019-10-17	Biophore India Pharmaceuticals Pvt. Ltd	Crystalline forms of (3α, 5β, 6α, 7α)-6-ethyl-3, 7-dihydroxycholan-24-oic acid (obeticholic acid) and processes thereof
CN110655550A (zh) *	2018-06-29	2020-01-07	江苏海悦康医药科技有限公司	(E)-3α-羟基-6-亚乙基-7-氧代-5β-胆甾烷-24-酸的制备方法
CN108794558B (zh) *	2018-07-03	2020-05-22	丽珠集团新北江制药股份有限公司	一种反应条件温和的奥贝胆酸制备方法
KR102887406B1 (ko)	2018-07-26	2025-11-19	칠드런즈 호스피탈 메디칼 센터	간-담도-췌장 조직 및 이를 제조하는 방법
GB201812382D0 (en)	2018-07-30	2018-09-12	Nzp Uk Ltd	Compounds
US20210261599A1 (en) *	2018-08-24	2021-08-26	Solara Active Pharma Sciences Limited	Process for the Preparation of Obeticholic Acid and Intermediates Used In the Process Thereof
AU2019339410A1 (en)	2018-09-12	2021-04-15	Children's Hospital Medical Center	Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
CN113271951A (zh) *	2018-11-08	2021-08-17	英特塞普特医药品公司	使用奥贝胆酸的方法
CN109535217B (zh) *	2018-11-13	2020-04-14	丽珠集团新北江制药股份有限公司	一种奥贝胆酸的精制方法
EP3911647B1 (en)	2019-01-15	2023-12-13	Gilead Sciences, Inc.	Isoxazole compound as fxr agonist and pharmaceutical compositions comprising same
WO2020160371A1 (en)	2019-02-01	2020-08-06	The University Of Hong Kong	Innervated organoid compositions and methods of making same
CA3233305A1 (en)	2019-02-19	2020-08-27	Gilead Sciences, Inc.	Solid forms of fxr agonists
CN114144185A (zh)	2019-05-30	2022-03-04	英特塞普特医药品公司	用于治疗胆汁淤积性肝病的包含fxr激动剂和贝特类的药物组合物
CR20240234A (es)	2019-05-31	2024-07-09	Sage Therapeutics Inc	ESTEROIDES NEUROACTIVOS Y COMPOSICIONES DE ESTOS (Divisional 2021-629)
WO2020243633A1 (en)	2019-05-31	2020-12-03	Children's Hospital Medical Center	Shaped organoid compositions and methods of making same
WO2020243613A1 (en)	2019-05-31	2020-12-03	Children's Hospital Medical Center	Methods of generating and expanding hematopoietic stem cells
WO2021029656A1 (ko) *	2019-08-14	2021-02-18	주식회사 바이오톡스텍	하이드로퀴논 유도체, 및 오베티콜릭산을 포함하는 비알콜성 지방간염의 예방 또는 치료용 약학조성물
CN112824425B (zh) *	2019-11-21	2023-10-03	成都西岭源药业有限公司	一种6-位烯基取代胆酸化合物及其制备方法和应用
US20230201222A1 (en) *	2020-05-13	2023-06-29	Children's Hospital Medical Center	Alleviation of liver injury by activating the signaling pathway mediated by farnesoid x receptor
WO2022051321A1 (en)	2020-09-03	2022-03-10	Coherus Biosciences, Inc.	Fixed dose combinations of chs-131 and a fxr agonist
KR102526452B1 (ko) *	2020-10-28	2023-04-27	(주)델로	관절 구조를 포함하는 토이 로봇
CN114644670A (zh) *	2020-12-17	2022-06-21	四川弘远药业有限公司	奥贝胆酸和对氨基苯甲酸的共晶及其制备方法
CN114236027B (zh) *	2021-12-22	2024-01-12	中山百灵生物技术股份有限公司	一种(E)-6-亚乙基-3α-羟基-7-酮基-5β-胆甾烷-24-酸的检测方法
US12343351B2 (en)	2022-03-25	2025-07-01	Rutgers, The State University Of New Jersey	Pulmonary function treatment

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4072695A (en)	1972-09-21	1978-02-07	Intellectual Property Development Corporation	3α,7α-Dihydroxy-cholanic acid derivatives
IT1137459B (it) *	1981-04-14	1986-09-10	Erregierre Spa	Prodesso per la preparazione di acido ursodeossicolico ad alta purezza
DE3366932D1 (en)	1982-07-29	1986-11-20	Lehner Ag	New derivatives of biliary acids, process for the production thereof and pharmaceutical compositions containing the same
IT1206112B (it)	1983-04-29	1989-04-14	Lehner Ag	Nuovi derivati di acidi biliari, procedimento per la loro preparazione e relative composizioni farmaceutiche.
IT1212835B (it)	1983-08-18	1989-11-30	Lehner Ag	Derivati di acidi biliari, procedimento per la loro preparazione e relative composizioni farmaceutiche.
US4892868A (en)	1984-08-17	1990-01-09	Gipharmex, S.P.A.	Derivatives of biliary acids, process for the production thereof and corresponding pharmaceutical compositions
IT1196377B (it)	1984-12-21	1988-11-16	Lehner Ag	Derivati di acidi biliari,procedimento per la loro preparazione e relative composizioni farmaceutiche
US5023252A (en)	1985-12-04	1991-06-11	Conrex Pharmaceutical Corporation	Transdermal and trans-membrane delivery of drugs
IT1223313B (it)	1987-10-20	1990-09-19	Gipharmex Spa	Derivati di acidi biliari loro preparazione e composizioni farmaceutiche che li contengono
JPH0320265A (ja)	1989-02-10	1991-01-29	Meiji Seika Kaisha Ltd	アミノチアゾール酢酸誘導体並びにその製造法
US5175320A (en)	1989-04-17	1992-12-29	Giuliani S.P.A.	Fluorinated bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
IT1229570B (it)	1989-04-17	1991-09-04	Giuliani Spa	Derivati fluorurati di acidi biliari, loro preparazione e composizioni farmaceutiche che li contengono.
ES2074113T3 (es)	1989-12-13	1995-09-01	Mitsubishi Chem Corp	Nuevos derivados de acido pirazolil acrilico, utiles como fungicidas sistemicos para la proteccion de plantas y materiales.
AU1856997A (en)	1996-02-02	1997-08-22	Merck & Co., Inc.	Method for raising hdl cholesterol levels
GB9604242D0 (en)	1996-02-28	1996-05-01	Glaxo Wellcome Inc	Chemical compounds
GB9606805D0 (en)	1996-03-30	1996-06-05	Glaxo Wellcome Inc	Medicaments
EP0921798A1 (en)	1996-07-12	1999-06-16	Smithkline Beecham Plc	Novel treatment of leptine resistance
JP3600713B2 (ja)	1997-08-06	2004-12-15	東京応化工業株式会社	ポジ型ホトレジスト組成物
US6008237A (en)	1997-12-19	1999-12-28	Merck & Co., Inc.	Arylthiazolidinedione derivatives
CA2318731C (en)	1998-01-29	2012-05-29	Tularik Inc.	Ppar-gamma modulators
JP3146187B2 (ja) *	1998-06-26	2001-03-12	高砂香料工業株式会社	ジホスフィンオキシドの新規な製造方法
WO2000025134A1 (en)	1998-10-23	2000-05-04	Glaxo Group Limited	Assays for ligands for nuclear receptors
DE69940958D1 (de)	1998-12-23	2009-07-16	Glaxo Group Ltd	Bestimmungsmethode fur liganden der nuklearen rezeptoren
WO2000040965A1 (en)	1999-01-07	2000-07-13	Tularik, Inc.	Fxr receptor-mediated modulation of cholesterol metabolism
AU780658B2 (en)	1999-03-26	2005-04-07	City Of Hope	Method of affecting cholesterol catabolism using nuclear bile acid receptor
US20020132223A1 (en)	1999-03-26	2002-09-19	City Of Hope	Methods for modulating activity of the FXR nuclear receptor
EP1473042B1 (en)	1999-03-26	2006-06-21	City of Hope	Screening for FXR receptor modulators
CN1368884A (zh)	1999-06-11	2002-09-11	阿勒根销售公司	用于调节fxr受体活性的方法
US6906057B1 (en)	1999-06-11	2005-06-14	Allergan, Inc.	Methods for modulating FXR receptor activity
US6559188B1 (en)	1999-09-17	2003-05-06	Novartis Ag	Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
CA2386750A1 (en)	1999-10-22	2001-05-03	Merck & Co. Inc.	Pharmaceuticals for treating obesity
US6627636B2 (en)	2000-06-15	2003-09-30	Bristol-Myers Squibb Company	HMG-CoA reductase inhibitors and method
AU2001288623A1 (en)	2000-09-05	2002-03-22	Tularik, Inc.	Fxr modulators
US20020119958A1 (en)	2001-02-13	2002-08-29	Shinichiro Tojo	Therapeutic agent for hyperlipidemia
ES2248581T3 (es) *	2001-03-12	2006-03-16	Intercept Pharmaceuticals, Inc.	Esteroides como agonistas de fxr.
US7354726B2 (en)	2001-04-12	2008-04-08	Takeda Pharmaceutical Company Limited	Screening method
WO2003015777A1 (en)	2001-08-13	2003-02-27	Lion Bioscience Ag	Nr1h4 nuclear receptor binding compounds
ATE381542T1 (de)	2001-08-13	2008-01-15	Phenex Pharmaceuticals Ag	Nr1h4-kern-rezeptor-bindende verbindungen
US20070010562A1 (en)	2001-08-13	2007-01-11	Ulrike Bauer	Nr1h4 nuclear receptor binding compounds
US7112340B2 (en) *	2001-10-19	2006-09-26	Baxter International Inc.	Compositions of and method for preparing stable particles in a frozen aqueous matrix
MXPA04004657A (es) *	2001-11-14	2004-08-13	Teva Pharma	Formas amorfas y cristalinas de potasio de losartan y proceso para su preparacion.
US20030144360A1 (en)	2001-11-19	2003-07-31	Allergan Sales, Inc.	Composition and method for modulating BAR/FXR receptor activity
US20050107475A1 (en)	2002-03-21	2005-05-19	Jones Stacey A.	Methods of using farnesoid x receptor (frx) agonists
AU2003228485A1 (en)	2002-04-12	2003-10-27	The University Of Chicago	Farnesoid x-activated receptor agonists
US6987121B2 (en)	2002-04-25	2006-01-17	Smithkline Beecham Corporation	Compositions and methods for hepatoprotection and treatment of cholestasis
ITMI20021532A1 (it)	2002-07-12	2004-01-12	Roberto Pellicciari	Composti chimici
WO2004048349A1 (en)	2002-11-22	2004-06-10	Smithkline Beecham Corporation	Farnesoid x receptor agonists
WO2005032549A1 (en)	2003-09-26	2005-04-14	Smithkline Beecham Corporation	Compositions and methods for treatment of fibrosis
EP1568706A1 (en)	2004-02-26	2005-08-31	Intercept Pharmaceuticals, Inc.	Novel steroid agonist for FXR
WO2005092369A2 (en) *	2004-03-11	2005-10-06	Fresenius Kabi Deutschland Gmbh	Conjugates of hydroxyethyl starch and erythropoietin
PL1734970T3 (pl)	2004-03-12	2015-05-29	Intercept Pharmaceuticals Inc	Leczenie zwłóknienia z zastosowaniem ligandów FXR
JP2008509912A (ja) *	2004-08-10	2008-04-03	エグゼリクシス，インコーポレイテッド	医薬品としての複素環化合物
US20060252670A1 (en) *	2004-10-14	2006-11-09	Intercept Pharmaceuticals Inc.	Method of reducing drug-induced adverse side effects in a patient
ES2732251T3 (es)	2005-04-25	2019-11-21	Enterin Inc	Dilactato de escualamina cristalino
ITMI20050912A1 (it)	2005-05-19	2006-11-20	Erregierre Spa	Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
JP2007077123A (ja)	2005-09-16	2007-03-29	Shiono Chemical Co Ltd	非晶質セフジニル、その製造方法およびこれを含有する経口投与用医薬組成物
US7932244B2 (en)	2006-06-27	2011-04-26	Intercept Pharmaceuticals, Inc.	Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions
EP1894924A1 (en) *	2006-08-29	2008-03-05	Phenex Pharmaceuticals AG	Heterocyclic FXR binding compounds
CL2007003035A1 (es) *	2006-10-24	2008-05-16	Smithkline Beechman Corp	Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
KR101555716B1 (ko)	2007-01-19	2015-09-25	인터셉트 파마슈티컬즈, 인크.	Ｔｇｒ5 조절제로서의 23-치환 담즙산 및 이의 사용 방법
EP1947108A1 (en)	2007-01-19	2008-07-23	Intercept Pharmaceuticals, Inc.	TGR5 modulators and methods of use thereof
US8338628B2 (en)	2007-08-28	2012-12-25	City Of Hope	Method of synthesizing alkylated bile acid derivatives
EP2222645B1 (en) *	2007-11-15	2013-03-20	F. Hoffmann-La Roche AG	Benzimidazole derivatives and their use as fxr agonists
WO2011022838A1 (en)	2009-08-25	2011-03-03	British Columbia Cancer Agency Branch	Polyhydroxylated bile acids for treatment of biliary disorders
WO2010014836A2 (en)	2008-07-30	2010-02-04	Intercept Pharmaceuticals, Inc.	Tgr5 modulators and methods of use thereof
US20110190242A1 (en) *	2008-09-23	2011-08-04	Resolvyx Pharmaceuticals, Inc.	Compositions and methods for the treatment of inflammatory disease
DK2698375T3 (en)	2008-11-19	2018-05-28	Intercept Pharmaceuticals Inc	TGR5 modulators and methods for using them
CN102121547B (zh) *	2010-12-23	2013-01-16	拉卡萨安吉拉股份有限公司	用于管道接头的衬套和采用该衬套的管道接头
CN102372757B (zh) *	2011-10-31	2013-01-16	安徽科宝生物工程有限公司	酯化法制备猪胆汁中鹅去氧胆酸的方法
SI3336097T1 (sl)	2012-06-19	2021-07-30	Intercept Pharmaceuticals, Inc.	Priprava nekristalinične oblike obetiholne kisline

2013
- 2013-06-17 SI SI201331813T patent/SI3336097T1/sl unknown
- 2013-06-17 HK HK15112051.4A patent/HK1211296A1/xx unknown
- 2013-06-17 EP EP20190630.2A patent/EP3789394A1/en not_active Withdrawn
- 2013-06-17 CN CN202010196448.0A patent/CN111228278A/zh active Pending
- 2013-06-17 NZ NZ703072A patent/NZ703072A/en unknown
- 2013-06-17 PL PL17202916T patent/PL3336097T3/pl unknown
- 2013-06-17 IN IN2561MUN2014 patent/IN2014MN02561A/en unknown
- 2013-06-17 EA EA201990211A patent/EA201990211A1/ru unknown
- 2013-06-17 MX MX2014016062A patent/MX365059B/es active IP Right Grant
- 2013-06-17 KR KR1020157000110A patent/KR20150022974A/ko not_active Ceased
- 2013-06-17 US US13/919,734 patent/US9238673B2/en active Active
- 2013-06-17 CA CA3028207A patent/CA3028207A1/en not_active Abandoned
- 2013-06-17 BR BR122016011808-8A patent/BR122016011808B1/pt active IP Right Grant
- 2013-06-17 SG SG10201607230SA patent/SG10201607230SA/en unknown
- 2013-06-17 CN CN201380043964.8A patent/CN104781272A/zh active Pending
- 2013-06-17 KR KR1020187020294A patent/KR20180083966A/ko not_active Ceased
- 2013-06-17 ES ES17202916T patent/ES2822375T3/es active Active
- 2013-06-17 WO PCT/US2013/046150 patent/WO2013192097A1/en not_active Ceased
- 2013-06-17 NZ NZ734451A patent/NZ734451A/en not_active IP Right Cessation
- 2013-06-17 CA CA2877122A patent/CA2877122C/en active Active
- 2013-06-17 JP JP2015518485A patent/JP2015521621A/ja active Pending
- 2013-06-17 SG SG10201610434YA patent/SG10201610434YA/en unknown
- 2013-06-17 EP EP17202916.7A patent/EP3336097B1/en active Active
- 2013-06-17 KR KR1020197030749A patent/KR20190121871A/ko not_active Ceased
- 2013-06-17 EA EA201590040A patent/EA032347B1/ru unknown
- 2013-06-17 SG SG11201408501UA patent/SG11201408501UA/en unknown
- 2013-06-17 EP EP21195801.2A patent/EP3992201A1/en active Pending
- 2013-06-17 AU AU2013277429A patent/AU2013277429B2/en active Active
- 2013-06-17 PT PT172029167T patent/PT3336097T/pt unknown
- 2013-06-17 CA CA3047776A patent/CA3047776C/en active Active
- 2013-06-17 BR BR112014031828-0A patent/BR112014031828B1/pt active IP Right Grant
- 2013-06-17 EP EP13733181.5A patent/EP2861613A1/en not_active Withdrawn
- 2013-06-17 NZ NZ719360A patent/NZ719360A/en not_active IP Right Cessation
- 2013-06-17 KR KR1020167034255A patent/KR101881245B1/ko not_active Expired - Fee Related
- 2013-06-17 DK DK17202916.7T patent/DK3336097T3/da active
- 2013-06-18 TW TW102121547A patent/TWI673284B/zh not_active IP Right Cessation
2014
- 2014-12-14 IL IL236231A patent/IL236231A0/en active IP Right Grant
- 2014-12-19 CL CL2014003475A patent/CL2014003475A1/es unknown
- 2014-12-19 PH PH12014502835A patent/PH12014502835A1/en unknown
- 2014-12-19 MX MX2019005819A patent/MX2019005819A/es unknown
- 2014-12-30 CO CO14286414A patent/CO7240414A2/es unknown
2015
- 2015-07-30 CL CL2015002145A patent/CL2015002145A1/es unknown
- 2015-11-20 US US14/947,492 patent/US9732116B2/en active Active
- 2015-11-20 US US14/947,680 patent/US10155787B2/en active Active
- 2015-11-20 US US14/947,658 patent/US10047117B2/en active Active
- 2015-12-07 JP JP2015238204A patent/JP6527077B2/ja active Active
2016
- 2016-02-09 AU AU2016200832A patent/AU2016200832B2/en active Active
- 2016-12-16 JP JP2016244217A patent/JP2017075169A/ja not_active Withdrawn
2017
- 2017-04-25 US US15/496,398 patent/US10174073B2/en active Active
- 2017-06-15 AU AU2017204057A patent/AU2017204057B2/en active Active
2018
- 2018-03-04 IL IL257841A patent/IL257841A/en unknown
- 2018-07-23 JP JP2018137552A patent/JP2018172438A/ja not_active Withdrawn
- 2018-07-23 JP JP2018137553A patent/JP6877389B2/ja active Active
- 2018-08-26 IL IL261372A patent/IL261372A/en unknown
- 2018-10-05 AU AU2018241172A patent/AU2018241172B2/en active Active
- 2018-11-13 US US16/189,559 patent/US20190153020A1/en not_active Abandoned
2020
- 2020-04-06 AU AU2020202405A patent/AU2020202405A1/en not_active Abandoned
- 2020-04-13 JP JP2020071677A patent/JP6978544B2/ja active Active
2021
- 2021-01-06 US US17/142,870 patent/US20210395293A1/en not_active Abandoned
2023
- 2023-03-22 US US18/188,341 patent/US20230340010A1/en not_active Abandoned
2024
- 2024-02-08 US US18/436,527 patent/US20250011360A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HK1211296A1 (en)	2016-05-20
EP3336097B1 (en)	2020-08-19
BR122016011808B1 (pt)	2021-09-21
AU2017204057A1 (en)	2017-07-06
US9238673B2 (en)	2016-01-19
JP6978544B2 (ja)	2021-12-08
PL3336097T3 (pl)	2021-05-31
US10174073B2 (en)	2019-01-08
JP2015521621A (ja)	2015-07-30
IL261372A (en)	2018-10-31
JP2017075169A (ja)	2017-04-20
NZ703072A (en)	2016-06-24
AU2017204057B2 (en)	2018-11-01
BR112014031828A2 (pt)	2021-07-06
US20160215014A1 (en)	2016-07-28
EA201990211A1 (ru)	2019-06-28
EP3336097A1 (en)	2018-06-20
AU2018241172B2 (en)	2020-03-05
CL2015002145A1 (es)	2015-12-11
MX2019005819A (es)	2019-10-21
KR20160143894A (ko)	2016-12-14
US20190153020A1 (en)	2019-05-23
CA2877122A1 (en)	2013-12-27
IL257841A (en)	2018-04-30
IL236231A0 (en)	2015-02-01
SI3336097T1 (sl)	2021-07-30
US9732116B2 (en)	2017-08-15
US20250011360A1 (en)	2025-01-09
AU2018241172A1 (en)	2018-11-01
EP3992201A1 (en)	2022-05-04
US20160074419A1 (en)	2016-03-17
US20170226149A1 (en)	2017-08-10
CO7240414A2 (es)	2015-04-17
US10155787B2 (en)	2018-12-18
CA3047776A1 (en)	2013-12-27
DK3336097T3 (da)	2020-09-28
PH12014502835A1 (en)	2015-02-02
KR20180083966A (ko)	2018-07-23
KR20150022974A (ko)	2015-03-04
US20160176913A1 (en)	2016-06-23
JP2016074724A (ja)	2016-05-12
CN111228278A (zh)	2020-06-05
KR101881245B1 (ko)	2018-07-23
NZ734451A (en)	2018-12-21
EA201590040A1 (ru)	2015-05-29
TW201410699A (zh)	2014-03-16
US20210395293A1 (en)	2021-12-23
CA2877122C (en)	2020-04-28
TWI673284B (zh)	2019-10-01
US20130345188A1 (en)	2013-12-26
AU2016200832A1 (en)	2016-02-25
BR122016011808A2 (pt)	2018-12-11
MX2014016062A (es)	2015-07-17
ES2822375T3 (es)	2021-04-30
JP6877389B2 (ja)	2021-05-26
SG11201408501UA (en)	2015-01-29
EP3789394A1 (en)	2021-03-10
JP2020125317A (ja)	2020-08-20
JP2018184443A (ja)	2018-11-22
CA3047776C (en)	2022-10-18
WO2013192097A1 (en)	2013-12-27
KR20190121871A (ko)	2019-10-28
AU2013277429B2 (en)	2016-01-14
US10047117B2 (en)	2018-08-14
BR112014031828B1 (pt)	2021-12-21
IN2014MN02561A (pt)	2015-09-04
JP2018172438A (ja)	2018-11-08
EP2861613A1 (en)	2015-04-22
CA3028207A1 (en)	2013-12-27
SG10201610434YA (en)	2017-02-27
US20230340010A1 (en)	2023-10-26
AU2016200832B2 (en)	2017-05-18
AU2013277429A1 (en)	2015-01-22
EA032347B1 (ru)	2019-05-31
CL2014003475A1 (es)	2015-08-07
SG10201607230SA (en)	2016-10-28
AU2020202405A1 (en)	2020-04-30
NZ719360A (en)	2017-08-25
CN104781272A (zh)	2015-07-15
JP6527077B2 (ja)	2019-06-05
MX365059B (es)	2019-05-22

Publication	Publication Date	Title
SI3336097T1 (sl)	2021-07-30	Priprava nekristalinične oblike obetiholne kisline
ES2892029T5 (en)	2026-03-25	Formulations of enzalutamide
SG11201503646TA (en)	2015-07-30	Esterification of 2,5-furan-dicarboxylic acid
SG11201405958RA (en)	2014-10-30	Nicotine formulation
SG11201504134SA (en)	2015-07-30	External preparation
IL235802A0 (en)	2015-02-01	A new process for the preparation of 2-cyclopentyl-6-methoxy-isonicotinic acid
GB201501016D0 (en)	2015-03-04	Preparation of 18F-fluciclovine
PL399419A1 (pl)	2012-12-17	Sposób wytwarzania 4-metoksydihydrochalkonu
PL399418A1 (pl)	2012-12-17	Sposób wytwarzania 4-metoksydihydrochalkonu
IL236450A (en)	2016-08-31	Process for making 5-fluoro-h1-pyrazoles
EP2892903A4 (en)	2016-01-27	PROCESS FOR PREPARING TAZOBACTAM
ZA201405824B (en)	2015-11-25	Process for the preparation of substituted phenylpropanones
PL2908859T3 (pl)	2017-10-31	Formulacje arypiprazolu
HU229987B1 (en)	2015-04-28	Process for the preparation of pyrimidinyl-piperazines
GB201210088D0 (en)	2012-07-25	Odontalgic preparation
PL2890669T3 (pl)	2017-04-28	Sposób wytwarzania eteru dimetylowego
GB201211247D0 (en)	2012-08-08	Improved formulation
IL234771B (en)	2019-10-31	Nicotine formulation
PL399422A1 (pl)	2013-03-04	Sposób wytwarzania 2',4,4',6'-tetrahydroksydihydrochalkonu
PL399423A1 (pl)	2013-03-04	Sposób wytwarzania 2'-hydroksydihydrochalkonu
PL398695A1 (pl)	2012-09-24	Sposób wytwarzania 2'-hydroksydihydrochalkonu
GB201206178D0 (en)	2012-05-23	Formulations